May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
May 9, 2025, 10:15

Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer

Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X by Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, adding:

“I wish this was TCHP x 6 versus TDXd x 6 which would have been more relevant to US practice patterns which already avoid anthracyclines. While TCHP is incredibly toxic and I am eager to replace, if compelling, we will be escalating to 8 neoadj cycles vs 6.”

Quoting Erika Hamilton’s post:

“Another positive trial in breast cancer, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer. We’ve seen a lot of positive TDXd results, but this is the first in the early-stage setting!”

Read further.

Sarah Sammons responded to recent findings showing the benefit of TDXd followed by THP over ddAC-THP in early HER2-positive breast cancer. She highlighted the need for data aligned with U.S. practice, which typically avoids anthracyclines, and signaled openness to treatment adjustments based on compelling evidence.

More posts featuring Sarah Sammons and Erika Hamilton.